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Abstract
Background: Ceramide is an important second messenger that has diverse cellular and biological effect. It is a
specific and potent inducer of apoptosis and suppressor of cell growth. In leukemia, chemoresistance generally
developed due to deregulated ceramide metabolism. In combinatorial treatment strategies of leukemia, few
components have the capability to increases ceramide production. Manipulation in ceramide production by
physiological and pharmacological modulators therefore will give additive effect in leukemia chemotherapy.
Results: Here, we show that Withanolide D (C4b-C5b,C6b-epoxy-1-oxo-,20b, dihydroxy-20S,22R-witha-2,24-dienolide;
WithaD), a pure herbal compound isolated from Withania somnifera could effectively induces apoptosis in a dose
and time dependant manner both in myeloid (K562) and lymphoid (MOLT-4) cells being nontoxic to normal
lymphocytes and control proliferative cells. WithaD potentially augment ceramide production in these cells.
Downstream of ceramide, WithaD acted on MKK group of proteins and significantly increased JNK and p38MAPK
phosphorylation. Pharmacological inhibition of p38MAPK and JNK proves their cooperative action on WithaD-
induced cell death. Dissecting the cause of ceramide production, we found activation of neutral sphingomyelinase
and showed neutral-sphingomyelinase 2 (N-SMase 2) is a critical mediator of WithaD-induced apoptosis.
Knockdown of N-SMase 2 by siRNA and inhibitor of N-SMase (GW4869) significantly reduced WithaD-induced
ceramide generation and phosphorylation of MKK4 and MKK3/6, whereas phosphorylation of MKK7 was moderately
regulated in leukemic cells. Also, both by silencing of N-SMase 2 and/or blocking by GW4869 protects these cells
from WithaD-mediated death and suppressed apoptosis, whereas Fumonisin B1, an inhibitor of ceramide synthase,
did not have any effect. Additionally, WithaD effectively induced apoptosis in freshly isolated lymphoblasts from
patients and the potent cell killing activity was through JNK and p38MAPK activation.
Conclusion: Our results demonstrate that WithaD enhance the ceramide accumulation by activating N-SMase 2,
modulate phosphorylation of the JNK and p38MAPK and induced apoptosis in both myeloid and lymphoid cells
along with primary cells derived from leukemia patients. Taken together, this pure herbal compound (WithaD) may
consider as a potential alternative tool with additive effects in conjunction with traditional chemotherapeutic
treatment, thereby accelerate the process of conventional drug development.
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Introduction
Apoptosis is a regulated biochemical process that bal-
ance between cell survival and death, maintaining the
normal tissue homeostasis [1]. In the molecular event of
apoptosis, it has been thought that mainly kinases and
caspases play the central role by mediating and transdu-
cing signals, but emerging reports showed that lipid
molecules also play a crucial role. Different kinds of
lipids reside in cell membrane and they could be
released and transduce a signal from extracellular sti-
muli [2,3]. Among them, sphingolipid ceramide is a key
lipid second messenger that regulates diverse cellular
processes like cell cycle arrest, cell death, differentiation,
ageing and immune response [4]. In fact, during the
apoptosis, the concomitant ceramide formation from
sphingomyelin hydrolysis brings the changes in mem-
brane topology, which is the hallmark of apoptosis [5].
Ceramide regulates diverse stress signaling pathways by
affecting transcription (through c-Jun), translation
(through RAX), and the apoptotic machinery in many
ways. Additionally, survival pathways mediated by PKC
and Akt were inactivated by ceramide [6]. The impor-
tance of ceramide regulated diverse signaling pathways
and its responsibility in apoptosis is therefore obvious
and manifold. Hence, defects in ceramide metabolism
potentially affect cellular responses to the chemotherapy
or other anti-cancer strategies, making the cells more
resistant and contribute to the multi drug resistance [7].
This information advocates the candidature of ceramide
as a potent drug target and implies its role towards the
response against malignancy.
Leukemia is heterogeneous group of neoplasm arising
from the malignant transformation of haematopoietic
cells [8-11]. In lymphoid leukemia, though 80% of
patients achieved clinical remission in the Western
countries, but in developing and under developed coun-
tries the scenario is quiet different. The problems still
persist, as relapse rate is very high due to the presence
of non-detectable yet existing leukemic cell mass known
as minimal residual disease [12-14]. Another major pro-
blem is the development of multi drug resistance in
these patients [15]. Obeid et al [16], in their classic
paper reported that in leukemia, C2-ceramide, a syn-
thetic ceramide analog is capable of inducing DNA frag-
mentation. Interestingly, resistance to radiation therapy
developed due to defective ceramide metabolism was
reported in Burkitt’s lymphoma and myeloid leukemia
[17]. Thus, deregulation of ceramide production may
play an important role in chemoresistance. Any altera-
tion in ceramide metabolism is often harmful to leuke-
mia patient due to less ceramide deposition. Thereby
manipulation of ceramide metabolism in patients to pro-
mote ceramide production may be helpful in
chemotherapeutic treatment [18]. Both in irradiation
and chemotherapeutic drug treatment strategy, the com-
mon components encourage ceramide production in
leukemia [19-21]. Hence, a novel compound that could
augment the production of ceramide during chemother-
apy, potentiating the cell killing and leading to more
effective anti-leukemic strategies, is on demand.
Withanolide D (WithaD) is a pure herbal compound
purified from the ancient medicinal plant Withania
somnifera [22]. We have recently demonstrated that
WithaD induced apoptosis in both myeloid (K562) and
lymphoid (MOLT-4) cells and suppress tumor cell
growth in K562 xenograft (personal communication).
Here, we observed that WithaD could enhance the cera-
mide accumulation by activating neutral-sphingomyeli-
nase (N-SMase) and thus modulate the phosphorylation
of stress kinases, JNK and p38MAPK leading to apopto-
sis in these leukemic cells and primary cells derived
from leukemia patients. Knockdown of N-SMase 2 by
siRNA and inhibitor of N-SMase (GW4869) significantly
reduced WithaD-induced ceramide generation and regu-
lated phosphorylation of MKK4 and MKK3/6 and
MKK7. To the best of our knowledge, there was no
study so far exploit the insight of sphingomyelinase-cer-
amide cascade as a result of WithaD treatment by
demonstrating N-SMase 2 as a critical mediator of
WithaD-induced apoptosis.
Materials and methods
Withanolide D
WithaD (M.W 470.6) was purified in high yields from
Withania somnifera (Chemotype NMITLI-135, patent
submitted) leaves as described previously [22]. The pure
compound was crystallized and analyzed by IR, mass, 1H-
NMR and 13C-NMR spectral analysis [Additional file 1].
The chemical structure of WithaD is C4b-hydroxyC5b,
C6b-epoxy-1-oxo-,C20b,dihydroxy-20S,22R-witha-2,24-
dienolide (Figure 1A). It was dissolved in absolute etha-
nol as 0.5 mM solution and stored at -70°C.
Reagents
Recombinant E. coli diacylglycerol (DAG) kinase, 3-(4,
5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bro-
mide (MTT), anti-ceramide antibody, standard ceramide
and sphingomyelin were from Sigma (St Louis, MO).
APO-DIRECT kit, Bcl2, Bax, caspase 3 antibodies and
7-aminoactinomycin D (7-AAD) were from BD (San
Diego, CA, USA). Cocktail protease inhibitor, inhibitors
of N-SMase (GW4869), ceramide synthase (Fumonisin
B1), JNK (SP600125) and p38MAPK (SB203580) were
purchased from Calbiochem. Phospho-SAPK/JNK path-
way sampler kit, phospho-p38MAPK pathway sampler
kit, anti-phospho-MKK7, anti-MKK7, anti-phospho-
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SEK1/MKK4, anti-SEK1/MKK4, anti-MKK3, anti-JNK,
anti-p38, anti-ERK, anti-phospho-ERK, b-actin were
from Cell Signaling technology. Custom primers, siR-
NAs, PCR reagent kit, RNase free DNase I and Amplex
Red sphingomyelinase assay kit, Opti-MEM™, Lipofecta-
mine 2000 were purchased from Invitrogen (USA).
Clinical samples, cell lines and culture conditions
The study involved fresh leukemia cells obtained from
clinically confirmed leukemia patients (n = 22) com-
prises pediatric myeloid (n = 7) leukemia, B-(n = 10)
and T-(n = 5) ALL, enriched with Ficoll gradient centri-
fugation. The diagnosis was established on the basis of
morphological examination and immunophenotyping by
four colour FACS analysis using commercially available
lineage specific standard antibodies whose expression
are known to aberrant in leukemia [9,13]. The clinical
samples were collected at Kothari Medical Center and
sent to the Indian Institute of Chemical Biology. Normal
healthy individuals (n = 7) of both sexes served as con-
trols. The Institutional human ethical committee had
approved the study and samples were taken with the
Figure 1 Anti-proliferative effect of WithaD. (A) Chemical structure of WithaD. (B) Morphological changes induced by WithaD in K562, MOLT-
4 and Vero cells, as demonstrated by phase contrast microscopy. (C) Effect of WithaD (0-5 μM) on the cell viability of K562 and MOLT-4 cells
after 24 and 48 hr as demonstrated by MTT assay. (D) Normal lymphocytes were isolated form normal blood, cultured for 48 hr in the presence
of WithaD at concentration ranged from 0-20 μM and checked the cell viability by trypan blue dye exclusion assay. (E) Flow cytometric analysis
revealed in situ DNA fragmentation by TUNEL assay in WithaD treated MOLT-4 (0.5 μM) and K562 (1.5 μM) cells at indicated time. The plots are
representative of three independent experiments. The percentages of TUNEL positive cells were indicated in respective panel.
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consent of the donors, patients, or their parents or
guardians.
A representative cell line from chronic myeloid (K562)
and T-lineage acute lymphoid origin (MOLT-4) were
obtained from American Type Culture Collection
(ATCC, Manassas, VA). Cells were cultured in RPMI-
1640 medium supplemented with 10% fetal bovine
serum (FBS; Gibco/BRL, NY, USA) in 5% CO2-95% air
humidified atmosphere at 37°C.
MTT assay and Trypan blue dye exclusion assay
Cytotoxicity of WithaD against MOLT-4, K562 and pri-
mary cells from leukemic patients was determined by 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bro-
mide (MTT) and trypan blue dye exclusion assay.
Briefly, Cells (2 × 104/250 μl/well) in log phase were
seeded on 96-well tissue culture plates, incubated with
freshly prepared WithaD (0-10 μM) for 24 and 48 hours
at 37°C in a humidified atmosphere containing 5% CO2.
After incubation, MTT (0.1 mg/well) was added, incu-
bated for an additional 4 hr at 37°C. After plate centrifu-
gation, the resultant pellet was dissolved in DMSO.
Absorbance of the resultant formazon was measured at
550 nm using an plate reader (Multiskan Ex, Thermo
electron corporation). Cell viability was also assessed by
counting viable cells in each well in triplicate counting
under light microscope. Peripheral blood mononuclear
cells (PBMCN) from normal healthy individuals were
exposed to WithaD under identical conditions. In paral-
lel, a normal proliferative cell line (Vero, ATCC) was
cultured in IMDM medium with 10% FBS and incu-
bated with 10 μM of WithaD for 20 hr in similar condi-
tion. Each experiment was performed at least three
times and in triplicates.
Apoptosis assay
In situ DNA fragmentation was determined by TUNEL
assay using APO-DIRECT kit according to manufac-
turer’s instruction. Briefly, cells (1 × 106) were washed
with PBS, fixed in 1% paraformaldehyde and incubated
in chilled 70% ethanol. After washing, cells were resus-
pended in staining solution containing TdT enzyme and
FITC-dUTP and further incubated in PI/RNase staining
buffer and analyzed by flow cytometer. For AnnexinV-7-
AAD assay, cells (1 × 106) were treated with WithaD
and processed as reported earlier. Phosphatidylserine
externalization was analyzed by double staining the cells
with FITC-annexinV and 7-AAD reported earlier
[23,24]. Cells were acquired and the data were analyzed
by CellQuest Pro software (BD FACSCalibur).
Flow cytometry
To check the status of the phosphorylation level of
p38MAPK and JNK, cells were incubated for 0-4 hr
with WithaD, washed and incubated with respective
mAbs. Washed cells were subsequently incubated with
PE-secondary antibody and analyzed by flow
cytometer.
Western blot analysis
Cells (1 × 106) were treated WithaD and equal amount
of protein were electrophoresed on SDS-PAGE (10-15%)
and electrotransferred to nitrocellulose membranes. The
membrane was then blocked by 2% PBS-BSA, probed
with primary antibody overnight at 4°C, washed with
PBS containing 0.1% Tween-20 and incubated with the
appropriate horseradish peroxidase (HRP)-conjugated
secondary antibody. The immunoreactive protein was
identified either by the DAB-H2O2 system or ECL
system [Pierce, USA, [25,26]].
Ceramide Quantification
The ceramide level in cells was checked by intracellu-
lar immunostaining [27]. Briefly, cells were fixed and
permeabilized with 1% formaldehyde/methanol in PBS
for 10 min at room temperature. After washing, cells
were incubated with anti-ceramide mAb, followed by
FITC-labeled secondary antibody and the generation of
ceramide was determined using flow cytometer. For
blocking assay, cells were pretreated with Fumonisin
B1 and/or GW4869 for 1 hr, followed by WithaD
treatment for 2 hr and subsequently ceramide level
were checked.
Ceramide content was also measured by diacylgly-
cerol (DAG) kinase assay [28]. Neutral lipids were
extracted as described previously [29]. Briefly, equal
number of cells (5 × 106) from treated and untreated
were taken and cell pellets were disrupted by three
cycles of freezing and thawing and homogenized by 30
s sonication at 10 watt. The aqueous pellets were
extracted using chloroform/methanol (2:1, vol/vol) to
obtain a final ratio of chloroform/methanol/water
(8:4:2.4, v/v/v). After vortex and 15 min centrifugation
at 1000 × g, the lower phase containing neutral glycoli-
pids were recovered and evaporated under nitrogen.
The samples were then resuspended in chloroform/
methanol (2:1, v/v) and ceramide content was mea-
sured using [g32P]-ATP (10 μCi) and 35 μg/ml recom-
binant E. coli DAG kinase at pH 6.5. Radioactive
ceramide-1-phosphate was resolved by thin layer chro-
matography on silica gel 60 HPTLC plates using a sol-
vent system of chloroform:methanol:acetic acid
(65:15:5, v/v/v). Incorporated radioactivity was quanti-
fied using liquid scintillation counter.
In parallel, the samples were also loaded on a silica gel
60 HPTLC plate and similarly chromatographed along
with standards (ceramide, SM). The plate was charred
to visualize the bands.
Mondal et al. Molecular Cancer 2010, 9:239
http://www.molecular-cancer.com/content/9/1/239
Page 4 of 17
Sphingomyelinase Assay
N-SMase activity was measured using Amplex Red
sphingomyelinase assay kit using manufacturer’s proto-
col. Briefly, protein (50 μg) was diluted in assay buffer
containing Tris-HCl (0.1 M), MgCl2 (10 mM), pH 7.4
and added (100 μl/well) to 96 well plate. Finally, the
working solution (100 μl) containing alkaline phospha-
tase (8 U/ml), choline oxidase (0.2 U/ml), Amplex Red
(0.1 mM) and HRP (2 U/ml) along with sphingomyelin
(SM, 0.5 mM) was added to each well. The plate was
then incubated for 30 min at 37°C in dark. The
sequential breakdown of SM by N-SMase, alkaline
phosphatase and choline oxidase produce H2O2.
Finally, H2O2, in the presence of HRP, reacts with
Amplex Red reagent to generate the specific fluores-
cent product, resorufin. The fluorescent intensity was
measured immediately using Fluorescence plate Reader
(Hitachi, Tokyo, Japan.) at 571/585 nm excitation/
emission levels.
Acidic-SMase (A-SMase) activity was also measured
using the same kit but in two-step process. Here, the
cell lysate (100 μl/well) was diluted with sodium acetate
(50 mM) buffer, pH 5.0. Subsequently, SM solution (5
mM, 10 μl) was added and incubated for 1 hr at 37°C
for the generation of ceramide and phosphorycholine.
Finally, the working solution (100 μl) was added to each
well to react with phosphorylcholine for 45 min at 37°C.
The H2O2 generated in this process was measured as
stated above.
Scanning Electron Microscopy (SEM)
Cells (5 × 106) were treated with WithaD, incubated for
12 hr and then processed for morphological studies by
SEM [30]. Briefly, cells were directly fixed overnight
with glutaraldehyde (2.5%) solution in PBS, pH 7.2 and
over night in osmium tetraoxide (1%) in the same buf-
fer. The cell suspensions were dehydrated in an ethanol
gradation. After drying with carbon dioxide by the criti-
cal point method and sputter coating with gold samples
were examined on a SEM (VEGAII LSU, TESCAN,
Czech Republic) and at least 15 microscopic fields were
observed for each sample.
Semi-quantitative reverse transcription-PCR (RT-PCR)
Total RNA was extracted using RNeasy mini kit (Qia-
gen, USA) and reverse transcribed into cDNA with ran-
dom primer using Im-Pro-II-Reverse transcription
system (Promega, USA) as reported earlier [29]. The
PCR was carried out with specific primers (Table 1) in
PTC-100 (MJ Research, MA, USA) and products were
electrophoresed on agarose gel (1%) followed by staining
with ethidium bromide and visualized under UV light.
The signal intensity of the respective bands was mea-
sured by means of the Quantity one version 4.1.1 soft-
ware using BIORAD image analysis system (CA, USA).
RNAi mediated silencing
Three sets of sense and anti-sense stealth™ RNAi were
used for SMPD3 (Table 2). Cells (8 × 105 cells/2 ml/
Table 1 Primer sequences
Primer Primer sequence Fragment Position Primer
Length (bp)
Tm (°C)
Ceramide synthase (LASS2-001), size: 242 bp
Sense Primer 5’-TTCTTTGAGCTGTACGTGGCTA-3’ 549-571 22 60.07
Antisense primer 5’-TCTCGGAACTTCTTGAGGAGAC-3’ 790-768 22 59. 99
Acid sphingomyelinae (A-SMase), size: 146 bp
Sense Primer 5’-GAGTAGAGGCCTAAGTTGAC-3’ 2181-2201 20 50.74
Antisense primer 5’-GGAGTCCAAGTCTCTTATCT-3’ 2326-2346 20 49. 90
Neutral sphingomyelinase (SMPD2) size: 240 bp
Sense Primer 5’-ACAATCGACAGAAGGACATC-3’ 781-801 20 55.00
Antisense primer 5’-AGTTCTTGGGTACCATTGTG-3’ 1020-1000 20 54. 99
Neutral sphingomyelinase (SMPD3) size: 296 bp
Sense Primer 5’-TGTTACCCCAACAAGTGTAACG-3’ 1681-1703 22 59.82
Antisense primer 5’-TCGTCAGAGGAGCAGTTATCAA-3’ 1976-1954 22 60.02
Neutral sphingomyelinase (SMPD4) size: 177 bp
Sense Primer 5’-ATCCTGTGGAGTACAGCATC-3’ 864-884 20 55.04
Antisense primer 5’-TGTGGTACAGAGGACTGTCA-3’ 1040-1020 20 54.89
b-actin, size:137 bp
Sense Primer 5’-CGACAGGATGCAGAAGGAG-3’ 1014-1032 19 62
Antisense primer 5’-ACATCTGCTGGAAGGTGGA-3’ 1150-1132 19 58
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well) were plated at 50% confluences in a six well plate
in RPMI-1640 without antibiotics [31]. After 24 hr, lipo-
fectamine 2000 (10 μl) and opti-MEM™ medium (250
μl) without serum were mixed and incubated for 5 min
at room temperature. Separately, siRNA (150 nmol) was
mixed with opti-MEM™ medium (250 μl) and incubated
for 5 minute. Above two mixtures were combined and
further incubated for 30 min at room temperature for
complex formation and added to each well. After 8 hr
of incubation in the CO2 incubator, the medium con-
taining siRNA-lipofectamine 2000 complexes was
replaced with fresh 10% FCS containing RPMI-1640
without antibiotics and the cells were further cultured
as required.
Statistical analysis
All the results were expressed as the mean ± S.D. of
data obtained from three separate experiments. All sta-
tistical analyses were evaluated using graph pad prism
software (San Diego). Data were analyzed by the paired
t test, and P < 0.05 was considered statistically
significant.
Results
WithaD induced apoptosis in lymphoid and myloid
leukemia cells
WithaD (Figure 1A) induced extensive anti-prolifera-
tive activity against both K562 and MOLT-4 cells as
demonstrated by the total disintegration of cell mor-
phology, a decrease in cell density (Figure 1B) and
reduction in cell viability in a dose and time dependent
manner (Figure 1C). We have checked the viability of
normal lymphocytes in presence of WithaD (0-20 μM)
for 48 hrs. WithaD did not show any adverse effect on
normal lymphocytes (Figure 1D) as well as on a prolif-
erative normal cell line Vero (Figure 1B). We further
demonstrated 58.84% and 62.93% in situ nuclear DNA
fragmentation in K562 and MOLT-4 cells treated with
1.5 μM and 0.5 μM WithaD respectively at 48 hr (Fig-
ure 1E).
WithaD induced ceramide accumulation
To ascertain whether ceramide has any potential role in
WithaD induced cell death, we investigated the cera-
mide level using anti-ceramide antibody. K562 and
MOLT-4 cells were separately treated with WithaD at
different time points where we observed the increased
ceramide level in a time-dependent manner that maxi-
mized at 2 hr (Figure 2A). Interestingly, MOLT-4 cells
showed 61.55% even within 30 min of treatment
whereas K562 cells showed only 26.73% positivity. In
contrast, the endogenous ceramide levels were only 8-
10% in untreated cells. Additionally, we measured the
ceramide production by conventional DAG kinase assay.
The results revealed almost 4-5 fold increase in cera-
mide production in K562 and MOLT-4 cells within 90
min of WithaD treatment (Figure 2B). For further con-
firmation of ceramide accumulation as a result of
WithaD treatment, we isolated and separated neutral
glycolipids on HPTLC that also revealed augmented cer-
amide level (Figure 2C). Densitometry of the TLC plates
gives an approximate level of ceramide and SM. After
WithaD treatment, ceramide was enhanced 1.75 fold in
K562 and 1.83 fold in MOLT-4 cells as compared to
respective untreated cells (Figure 2D).
JNK and p38MAPK signals downstream of ceramide
Ceramide activates multiple signaling pathways includ-
ing the MAPKs. The members of MAPKs like ERK,
p38MAPK and JNK/SAPK play the central role in survi-
val and stress-induced cell death, in which ERK exerts
opposing effects of p38MAPK and JNK/SAPK on apop-
tosis [32]. To investigate whether ERK, JNK and
p38MAPK were involved, we monitored the effect of
WithaD on K562 and MOLT-4 cells for 1-6 hr. Activa-
tion of JNK and p38MAPK were detected as early as 1
hr treatments of WithaD and persisted till 6 hr, whereas
the reduced phosphorylation level of ERK was observed
(Figure 3A). To further confirm the activation of both
JNK and p38MAPK, we analyzed WithaD-treated
MOLT-4 and K562 cells by flow cytometry.
Table 2 siRNA sequences
Sequence Designated as
AJ250460- 1 siRNA 1
Sense 5’-CGAGCAGCCACCAAAUUGAAAGAGC-3’
Anti-sense 5’-GCUCUUUCAAUUUGGUGGCUGCUCGCU-3’
AJ250460- 2 siRNA 2
Sense 5’-GGUGCAGGUGGGAAGCACACCUCAG-3’
Anti-sense 5’-CUGAGGUGUGCUUCCCACCUGCACCUU-3’
AJ250460- 3 siRNA 3
Sense 5’-CCACUGCCAACGUCUGCCUCCUGCC-3’
Anti-sense 5’-GGCAGGAGGCAGACGUUGGCAGUGGCA-3’
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Figure 2 WithaD induces ceramide production in K562 and MOLT-4 cells. (A) Cells were treated with WithaD for 0-2 hr and the intracellular
ceramide content were determined using anti-ceramide antibody by flow cytometer as described in Materials and methods. Representative
histogram (top) and the percentages of positive cells (bottom) are shown. Results are the mean ± S.D. in duplicate in three independent
experiments. Asterisk indicates statistically significant difference (P < 0.005) in 2 hr treated cells with respect to untreated cells. (B) The
intracellular ceramide levels induced by WithaD in K562 and MOLT-4 cells were measured in the cell lipid extract by the diacylglycerol kinase
assay as described in Materials and methods. Cells were incubated with 1.5 and 0.5 μM WithaD respectively at the indicated times. * represents
statistical significant difference in ceramide level between 15 min and control, where P < 0.05. ** indicates significant difference in ceramide
level between 90 min and control. Data are expressed as % of control values and are the mean ± S.D. of three different experiments performed
in triplicate. (C) Level of ceramide and SM were determined in K562 and MOLT-4 cells separated in HPTLC Si 60 plates after 1 hr of WithaD
treatment, along with standard ceramide and SM. This is a representative profile of three independent experiments. (D) Densitometric
quantitation of ceramide and SM in lipid extracts from treated and untreated K562 and MOLT-4 cells. Data are mean ± SD of three independent
experiments.
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Interestingly, 39.71% p-JNK+ and only 3.51% p-p38
MAPK+ cells were observed in 1 hr in MOLT-4 cells
(Figure 3B), whereas 23% p-JNK+ and 3.1% p-p38
MAPK+ cells were observed in K562. However after 3
hr, in MOLT-4 p-p38 MAPK+ and p-JNK+ cells were
33.45% and 70.45% respectively, whereas in K562, p-p38
MAPK+ and p-JNK+ cells were 31.15% and 58.34%
respectively suggesting time dependent increase of both
JNK and p38 MAPK in both the cell lines.
To ascertain the role of activated JNK and p38MAPK
on WithaD-induced cell death, we used specific inhibi-
tors of JNK (SP600125) and p38MAPK (SB203580)
[33,34] and measured the rate of apoptosis after 48 hr
of WithaD treatment. The addition of SP600125 signifi-
cantly reduced the annexinV positivity from 40.92% to
25.83% in K562 whereas decrease of apoptosis by
SB203580 from 40.92% to 32.88%, which is not signifi-
cant (Figure 3C). Interestingly, when we treated the cells
Figure 3 Effect of WithaD on MAPKs in K562 and MOLT-4 cells. (A) K562 and MOLT-4 cells were treated with WithaD at the indicated time
and cell lysates were resolved in SDS-PAGE (10%). Western blot analysis showed higher level of phosphorylation of JNK and p38 whereas
reduced level of p-ERK was observed in different time duration. (B) MOLT-4 cells were treated with WithaD at the indicated time and p-JNK+ and
p-p38+ cells were analyzed by flow cytometry. (C) K562 and MOLT-4 cells were pretreated with SP600125 (10 μM) and SB203580 (10 μM) for 1
hr, then treated with withaD for another 48 hr and % of annexin V+ cells were determined using flow cytometer. Results are the mean ± S.D. in
duplicate in two independent experiments. *indicates statistically significant difference (P < 0.005) between SP600125 treated and untreated cells.
**indicates statistically significant difference (P < 0.005) between SP600125 + SB203580 treated and untreated cells. # considered not significant
difference (P = 0.125) between SB203580 treated and untreated cells.
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with both the inhibitors, apoptosis was further reduced
to 14.72% for K562. Similar trend was observed in
MOLT-4 cells. Therefore, our results suggest that JNK
and p38MAPK might work cooperatively and amplify
WithaD-induced apoptosis in leukemia cells.
Activation of JNK and p38MAPK occurs through a
common upstream regulator
Cellular stress and anti-cancer agents activates both JNK
and p38MAPK, but in a distinctively separate way [35].
MKK7 is a kinase that specifically activates JNK/SAPK
whereas MKK3/6 serves as a specific activator of
p38MAPK [36-38]. Here, in both the cell lines, MKK7
and MKK3/6 were activated within 30 min exposure of
WithaD (Figure 4A). Interestingly, another MEKK
homolog, SEK1/MKK4 was also activated within 30 min
to a greater extent under similar treatment. Hence, our
results might suggest that, SEK1/MKK4 was activated
upstream of MKK3/MKK6 and MKK7 due to WithaD
treatment. Activation of MKK4, MKK3/6 and MKK7
was also observed in a dose (0-4 μM) dependant manner
with WithaD (Figure 4B).
WithaD induces neutral-sphingomyelinase activation
upstream of ceramide
Intracellular ceramide may be generated either by de
novo biosynthesis through ceramide synthase or by
membrane sphingomyelin (SM) degradation catalyzed
by sphingomyelinases [39,40]. Therefore to ascertain the
source of ceramide production, we measured the mRNA
level of ceramide synthase, A-SMase and N-SMase.
Here, we observed a marked increase in N-SMase2
(SMPD3) mRNA level, which activated as early as 15
min in WithaD-treated MOLT-4 cells and gradually
decreased after 45 min (Figure 5A). However, N-SMase
2 mRNA level activated within 30 min and persisted till
120 min in WithaD-treated K562 cells as revealed by
densitometric analysis. In contrast, there were negligible
changes in SMPD2 and SMPD4 in both leukemic and
myeloid cells. No change in mRNA level of ceramide
synthase and A-SMase was also observed under similar
treatment.
We further measured the activity of both A-SMase
and N-SMase after treatment of WithaD at different
time points until 2 hr. Although N-SMase reached its
Figure 4 WithaD activates MKK group of kinases upstream of p38 and JNK. (A) K562 and MOLT-4 cells were treated with WithaD (1.5 and
0.5 μM respectively) for different time points. The level of phosphorylation of MKK4, MKK7 and MKK3/6 was determined in WithaD-treated cells
by Western blot analysis using appropriate anti-MKK antibody. b-actin served as loading control. (B) The level of phosphorylation of MKK4, MKK7
and MKK3/6 was further determined after 2 hr treatment with different amount (0-4 μM) of WithaD as described above.
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maximal activity within 45-60 min in K562, the highest
activity was observed even within 15 min in MOLT-4
cells, which subsequently decline within 2 hr (Figure
5B). The sharp decrease of N-SMase activity in MOLT-
4 as compared to K562 (p53 null) suggested some rela-
tionship between p53 and N-SMase activation because
p53 was known to regulate ceramide formation through
N-SMase activation in glioma cells.
N-SMase critically regulate ceramide production and
activation of stress kinases
To confirm the role of N-SMase in ceramide produc-
tion, we pretreated the cells separately with inhibitor of
N-SMase (GW4869) and ceramide synthase (Fumonisin
B1) [41,42] followed by WithaD treatment and mea-
sured the ceramide level. We observed that GW4869
mediated 30% reduction in K562 and 23% in MOLT-4
in ceramide level (Figure 6A). In contrast, fumonisin B1
treatment could not produce any significant change in
ceramide level that ruled out the possibility of ceramide
synthesis by de novo pathway rather than SM hydrolysis.
Additionally, we had knockdown the N-SMase2 activity
by silencing the SMPD3 gene using three sets of siRNA
and observed that each siRNA oligonucleotide have
potential silencing affect, where siRNA1 was most effec-
tive. As a result each set of siRNA potentially reduced
ceramide production (Figure 6B). These results indicated
that the source of accumulation of ceramide both in
Figure 5 WithaD induces N-SMase activation. (A) RT-PCR analysis of N-SMases, ceramide synthase, and A-SMase. K562 and MOLT-4 cells were
treated with WithaD (1.5 and 0.5 μM respectively) for 0-120 min. RNA was extracted from total cell lysate and RT-PCR was performed. The band
intensity was measured. This is one representative of three independent experiments. *indicates statistically significant difference (P < 0.005) with
respect to untreated cells. (B) Measurement of N-SMase activity using Amplex Red sphingomyelinase assay kit using manufacturer’s protocol in
K562 and MOLT-4 cells after WithaD (1.5 and 0.5 μM respectively) treatment. A-SMase activity was determined using the same kit by two-step
SMase assay as described in Materials and methods. *indicates statistically significant difference (P < 0.005) between 45 min activity and 0 min in
K562 cells whereas ** indicates significant difference (P < 0.005) in activity in MOLT-4 cells.
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Figure 6 Effect of Fumonisin B1, (GW4869) and N-SMase silencing on ceramide production, activation of MKK group of kinases and
regulation of WithaD-mediated apoptosis. (A) Effect of Fumonisin B1 (10 μM) and GW4869 (10 μM) on ceramide level induced by WithaD.
Cells were pretreated with inhibitors for 1 hr; incubated further 1 hr with WithaD and ceramide levels were measured by FACS. Each column
represented the mean ± S.D. in duplicate in three independent experiments. *indicates statistically significant difference (P < 0.005). (B) Effect of
SMPD3 silencing in WithaD mediated ceramide accumulation. Cells were transfected with SMPD3 specific siRNAs as described in materials and
methods. Ceramide level were measured by DAG kinase assay as described in Materials and methods. Results are the mean ± S.D. of two
independent experiments. * indicates statistical significant difference P < 0.05. (C) and (D) Consequence of N-SMase inhibition by GW4869 and
N-SMase silencing by siRNA1 on phosphorylation of MKK4, MKK3/6 and MKK7. K562 and MOLT-4 cells were pretreated with GW4869 (10 μM) for
1 hr and further incubated for 2 hr with 3 μM and 1 μM WithaD respectively. (E) Effect of Fumonisin B1 (10 μM) and GW4869 (10 μM) on cell
death. Cells were pretreated separately with the inhibitors for 1 hr and after 48 hr apoptosis were measured. Each column represented the mean
± S.D. in duplicate in three independent experiments. * indicates statistically significant difference (P < 0.005). ** indicates difference (p = 0.1250).
Etoposide was used as positive control. (F) Effect of SMPD3 silencing in WithaD treated cells. After 48 hr of transfection, apoptosis was measured.
Results are representative of three independent experiments. * indicates statistical significant difference, where P < 0.05.
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K562 and MOLT-4 cells could come from sphingomye-
lin hydrolysis rather than de novo synthesis suggesting
the role of N-SMase in ceramide production.
Next, to address whether N-SMase directly regulates
the activators of stress kinase JNK and p38MAPK, we
have silenced the N-SMase2 with siRNA1 and separately
also blocked it with its pharmacological inhibitor
GW4869. Subsequently we measured the phosphoryla-
tion of MKK4, MKK7 and MKK3/6 (Figure 6C-D). Inhi-
bition and silencing of N-SMase2 resulted in substantial
decrease in phosphorylation of MKK4 and MKK3/6 in
both the cell lines, suggesting the direct effect of N-
SMase. Interestingly, the phosphorylation level of MKK7
was moderately effected by N-SMase knockdown or
inhibition.
N-SMase regulates WithaD induce cell death
To confirm that N-SMase plays a crucial role in WithaD
mediated apoptosis, cells were pretreated with GW4869
with or without WithaD and further incubated for 48
hr. The % of annexinV+ cells after GW4869 treatment
significantly reduces from 55.63% to 39.67% in MOLT-4
and 43.25% to 21.89% in K562 cells (Figure 6E),
whereas, fumonisin B1 treatment showed not significant
(p = 0.1250) reduction of annexinV+ cells. When we
treated the cells with both the inhibitors, no substantial
reduction of apoptosis was observed indicating that pos-
sibly N-SMase activation was one of the main factor
responsible for WithaD-induced cell death. The results
were similar as observed in etoposide treated cells,
which was used as a positive control because it is a
known chemotherapeutic agent that induces apoptosis
via ceramide formation through N-SMase activation and
not A-SMase [43].
The pivotal role of N-SMase was further confirmed by
anti-sense knockdown assay, which showed that siRNA1
oligonucleotide eliminated 60-80% of apoptosis induced
by WithaD as demonstrated by lower annexinV and 7-
AAD positivity (Figure 6F).
WithaD induced apoptosis in lymphoblasts of leukemia
patients
To establish the in vivo condition, we have investigated
the effect of WithaD on fresh leukemia cells of clinically
confirmed B-(n = 10), T-(n = 5) ALL and myeloid (n =
7) patients. A dose dependent growth inhibition was
observed after 24 and 48 hr exposure in both myeloid
and lymphoid cells using trypan blue dye exclusion
assay (Figure 7A). Treatment with WithaD for 48 hr
resulted ~80% annexinV+ lymphoblasts in these patients
(Figure 7B). Results from representative lymphoid and
myeloid patients were shown. The morphological analy-
sis of patient cells with WithaD for 12 hr showed
significant changes under SEM, whereas untreated cells
remained unaltered (Figure 7C).
For further confirmation of the signaling pathway, we
demonstrated that the anti- and pro-apoptotic protein
level of Bcl-2 and Bax was changed in a time dependent
manner, in patients’ cells treated with WithaD as
demonstrated by Western blot analysis. Subsequently,
WithaD induces caspase 3 activation in these patients
(Figure 7D). Additionally, WithaD-treated patients cells
showed phosphorylation of JNK and p38MAPK in a
time dependent manner (Figure 7E). All these pre-clini-
cal studies using the patients’ samples suggested that
WithaD might have potential to kill the lymphoblasts in
vivo.
Discussion
Current investigations are giving new insight about the
roles of sphingolipids in cellular regulation of growth
suppression, apoptosis and signal transduction. Among
the sphingolipids, ceramide has emerged as an impor-
tant second signal mediator, having multiple cellular
and biochemical targets. In particular, ceramide act as a
potent cell death inducer and a specific cell growth sup-
pressor. Recently, it has been thought that generation of
ceramide is a universal feature of apoptosis [6,44]. Pre-
sently, a few drugs are available in combinatorial che-
motherapy, which could generate ceramide. Therefore,
to find pharmacological modulators that induce cera-
mide production in malignant cells by mounting a phy-
siological response and induce senescence is on prime
importance.
In the present study, we demonstrated rapid accu-
mulation of endogenous ceramide in WithaD treated
MOLT-4 cells. In fact, 61.55% cells were ceramide
positive just in 30 mins. WithaD showed almost four
fold increase in ceramide level within 2 hr in both the
cell lines suggesting that ceramide plays a crucial role
in WithaD-induced apoptosis. A number of phospha-
tase and kinases involved in stress signaling are acti-
vated/regulated by ceramide. Ceramide targets stress-
activated protein kinases (SAPKs) such as thecc-jun N
terminal kinases (JNKs), kinase suppressor of Ras
(KSR), and the atypical protein kinase C (PKC) iso-
form, PKCζ [45,46]. Ceramide is also capable of acti-
vating protein phosphatases such as protein
phosphatase 1 (PP1) and protein phosphatase 2A
(PP2A) [47]. Among the vast targets of ceramide, the
kinase signalling cascade was an important pathway in
the transduction of apoptotic signals initiated by stress
stimuli, and the main participant in this cascade were
JNK and p38MAPK as well as their upstream kinases
(MKKs) [48]. Extracellular stimuli activate MKK7 that
serves as a specific activator of JNK/SAPK, whereas in
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a similar mechanism, MKK3/6 activates p38MAPK.
However, besides MKK7 and MKK3/6, a dual specific
threonine tyrosine protein kinase MKK4 known to
phosphorylate and activates both JNK and p38MAPK
[49].
In our study, we found that downstream of ceramide,
both JNK and p38 were activated within 2-3 hr in
response to WithaD. Also, within 60 min, MKK4,
MKK3/6 and MKK7 were activated. Knockdown and
inhibition of N-SMase reveal that Posphorylation of
MKK4 and MKK3/6 were affected, whereas pMKK7
remain almost unaltered. These results suggested that
besides N-SMase induced direct activation of MKK4
and MKK3/6, MKK7 was parallely activated. Inhibition
of JNK and p38MAPK separately decreased WithaD-
induced apoptosis. However, the combined treatment of
SP600125 and SB203580 further reduced the annexinV+
cells, which gives the plausible explanation that these
two stress-related pathways worked cooperatively to
amplify the pro-apoptotic signal.
Figure 7 WithaD induced apoptosis in primary cells from both myeloid and lymphoid patients. (A) WithaD reduced the viability of the
cells from pediatric myeloid, T- and B-ALL patients in 24 and 48 hr in a dose dependent manner as assessed by trypan blue dye exclusion test.
(B) WithaD potentially induced apoptosis in primary cells from patients. WithaD treated primary cells from representative lymphoid and myeloid
patients showed increased annexin V+/PI- (down right quadrant) and annexin V+/PI+ (upper right quadrant) cells by flow cytometry. (C) A
representative SEM micrograph showing typical blebbing in cell membrane in untreated (×10000) and treated (×10000) lymphoblast. (D) Cell
lysates of primary cells from patients were resolved in 10% SDS-PAGE. Western blot analysis showed the cleaved caspase 3, changes in Bcl-2 and
Bax expression, after WithaD treatment in a time dependent manner. b-actin was used as loading control. (E) Cell lysates of primary cells from
patients were resolved in 10% SDS-PAGE. Western blot analysis showed enhanced phosphorylation of JNK and p38 MAPK in response to WithaD
treatment in a time dependent manner. b-actin was used as loading control.
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Ceramide is a known important second signal effector
molecule. Several lines of evidence indicate that under
stressed condition, sphingomyelin turnover is induced
resulting in its breakdown and increase in ceramide
level. Intracellular ceramide is primarily generated,
either by sphingomyelin hydrolysis via the action of
sphingomyelinase or by de novo pathways involving cer-
amide synthase [6,35,50-52]. N-SMase and A-SMase
have been demonstrated to involve the formation of cer-
amide in response to apoptotic inducers including che-
motherapeutic agents [53,54]. On the contrary,
sphingosine kinase (SHPK) is an enzyme that produces
sphingosine 1-phosphate (S1P) from the ceramide
breakdown product sphingosine, which help in survival.
Therefore, these enzymes play crucial role determining
cells fate. Interestingly, in leukemia, it was reported that
SHPK1 was upregulated, whereas N-SMase level was
decreased. So, either the decrease of N-SMase or
increase in SHPK1 resulted in lower ceramide/SIP ratio,
which helps in the survival of lymphoblasts [55]. Our
result revealed an increase in intracellular ceramide con-
tent accompanying with SMPD3 activation as an early
event of WithaD treatment, suggesting WithaD possibly
hit the sphingomyelin hydrolysis by N-SMase 2 to gen-
erate ceramide, which may modify the ceramide/SIP
ratio paves the way from survival to death. Furthermore,
inhibition of N-SMase by GW4869 or silencing of
SMPD3 by specific siRNAs protects the cells from the
Figure 8 Probable mechanism of WithaD induced apoptosis of K562 and MOLT-4.
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cell death suggesting the importance of N-SMase activa-
tion. Recently, Ito et al reported that three Sp1 motifs
located between -148 and -42bp upstream of the first
exon of N-SMase were important in its activation, at
least by Daunorubicin induction [56]. However, the
transcriptional regulation of N-SMase activation by
WithaD was not clear and yet to be determined. Many
studies suggested a connection between oxidative stress
and N-SMase activation. In fact, early ROS production
is a critical event in ceramide generation [57] and cell
death. Therefore, we have investigated the production of
ROS at early time point as maximal activation of N-
Smase was observed within 2 hr exposure of WithaD.
However, WithaD treatment did not produce ROS
within 0-2 hr in both the cell lines under this experi-
mental condition suggesting that WithaD mediated N-
SMase activation was possibly ROS independent.
Natural products have received increasing attention
for the search of novel cancer preventive and therapeu-
tic agent. However, the pharmacological activity and
molecular targets of most of the ancient treatment and
their bioactive compounds are ignored and not well stu-
died [58]. However, many naturally occurring plant pro-
ducts have the potential to target multiple signaling
pathways. WithaD is isolated from a well known medic-
inal plant through cross-breeding of germplasm lines in
high yields. To the best of our knowledge, pharmacolo-
gical investigation of pure WithaD is totally absent,
therefore, demanding such investigations. Recently, we
have observed WithaD induced in vitro and in vivo cell
death in leukemia (personal communication). Here we
showed that (a) not only human myeloid (K562) and
lymphoid (MOLT-4) cell lines but also primary cells
from leukemia patients are highly sensitive to growth
inhibition by WithaD in a dose and time dependant
manner; (b) WithaD-mediated apoptosis was through
the activation of N-SMase 2 and accumulation of cera-
mide content and (c) ceramide activate MKK group of
proteins, leading to JNK and p38MAPK phosphoryla-
tion, resulting in their cooperative action to transduce
the death signal. These results provide a basic mechan-
ism which indicate that WithaD activate multiple signal-
ling cascade to induce apoptosis in leukemia (Figure 8).
These findings suggest that WithaD is a promising her-
bal compound that may be useful in future novel anti-
leukemia strategies by targeting multiple pathways along
with ceramide accumulation through N-SMase 2
activation.
Patent
A novel chemotype of Ashwagandha (Withania somni-
fera) named ‘NMITLI-135’ that lacks withaferin-A and
withanone and hyper accumulates withanolide D and
glycowithanolide withanoside VI in leaf. (No.
187NF2007).
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